CN101703770A - 多价性蛋内dna疫苗 - Google Patents
多价性蛋内dna疫苗 Download PDFInfo
- Publication number
- CN101703770A CN101703770A CN200910212389A CN200910212389A CN101703770A CN 101703770 A CN101703770 A CN 101703770A CN 200910212389 A CN200910212389 A CN 200910212389A CN 200910212389 A CN200910212389 A CN 200910212389A CN 101703770 A CN101703770 A CN 101703770A
- Authority
- CN
- China
- Prior art keywords
- dna
- virus
- polyvalency
- birds
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010041986 DNA Vaccines Proteins 0.000 title abstract description 27
- 229940021995 DNA vaccine Drugs 0.000 title abstract description 23
- 241000271566 Aves Species 0.000 claims abstract description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 239000012634 fragment Substances 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 230000001681 protective effect Effects 0.000 claims abstract description 11
- 241000700605 Viruses Species 0.000 claims description 87
- 108020004414 DNA Proteins 0.000 claims description 77
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 238000011238 DNA vaccination Methods 0.000 claims description 33
- 241000287828 Gallus gallus Species 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 238000010276 construction Methods 0.000 claims description 22
- 208000027312 Bursal disease Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 13
- 238000004026 adhesive bonding Methods 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 8
- 230000008105 immune reaction Effects 0.000 claims description 7
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 4
- 101150093578 VP2 gene Proteins 0.000 claims description 4
- 102000007469 Actins Human genes 0.000 claims description 3
- 108010085238 Actins Proteins 0.000 claims description 3
- 101150008820 HN gene Proteins 0.000 claims description 3
- 241000701447 unidentified baculovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- 241000272814 Anser sp. Species 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 abstract description 30
- 239000000427 antigen Substances 0.000 abstract description 11
- 230000003612 virological effect Effects 0.000 abstract description 11
- 108700005077 Viral Genes Proteins 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000028993 immune response Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 44
- 241000711450 Infectious bronchitis virus Species 0.000 description 35
- 235000013330 chicken meat Nutrition 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 229920001184 polypeptide Polymers 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 102000002322 Egg Proteins Human genes 0.000 description 16
- 108010000912 Egg Proteins Proteins 0.000 description 16
- 210000004681 ovum Anatomy 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 241000700662 Fowlpox virus Species 0.000 description 14
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 14
- 239000013615 primer Substances 0.000 description 13
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 12
- 241000132980 Turkey adenovirus 3 Species 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000012447 hatching Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 241000713826 Avian leukosis virus Species 0.000 description 8
- 101710081079 Minor spike protein H Proteins 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 101710114810 Glycoprotein Proteins 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101710167605 Spike glycoprotein Proteins 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 208000002979 Influenza in Birds Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 201000002491 encephalomyelitis Diseases 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 241000725585 Chicken anemia virus Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 2
- 241000711931 Rhabdoviridae Species 0.000 description 2
- 101150027674 S1 gene Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 101150036700 VP3 gene Proteins 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 101150029683 gB gene Proteins 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 108091069025 single-strand RNA Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 101710195101 Flagellar filament outer layer protein Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101150024766 VP1 gene Proteins 0.000 description 1
- 108091034135 Vault RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36254702P | 2002-03-08 | 2002-03-08 | |
| US60/362,547 | 2002-03-08 | ||
| US10/377,718 US7029681B2 (en) | 2002-03-08 | 2003-03-04 | Multiple and multivalent DNA vaccines in ovo |
| US10/377,718 | 2003-03-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN038080001A Division CN1646157B (zh) | 2002-03-08 | 2003-03-06 | 多重性和多价性蛋内dna疫苗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101703770A true CN101703770A (zh) | 2010-05-12 |
Family
ID=27807969
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910212389A Pending CN101703770A (zh) | 2002-03-08 | 2003-03-06 | 多价性蛋内dna疫苗 |
| CN038080001A Expired - Fee Related CN1646157B (zh) | 2002-03-08 | 2003-03-06 | 多重性和多价性蛋内dna疫苗 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN038080001A Expired - Fee Related CN1646157B (zh) | 2002-03-08 | 2003-03-06 | 多重性和多价性蛋内dna疫苗 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7029681B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1490105B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4999258B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101703770A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003216531B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0308365B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2478081C (cg-RX-API-DMAC7.html) |
| IL (2) | IL163859A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04008692A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003075843A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111733143A (zh) * | 2012-03-30 | 2020-10-02 | 法国诗华动物保健公司 | 多价重组禽疱疹病毒和用于免疫禽类的疫苗 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037506B2 (en) * | 2002-03-08 | 2006-05-02 | Schweltzer Chemical Corporation Ltd. | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry |
| WO2009076668A2 (en) * | 2007-12-13 | 2009-06-18 | Alpharma, Inc. | Bacteriophage preparations and method of use thereof |
| WO2013057235A1 (en) * | 2011-10-21 | 2013-04-25 | Intervet International B.V. | Recombinant nonpathogenic mdv vector providing multivalent immunity |
| IN2014CN02681A (cg-RX-API-DMAC7.html) | 2011-10-21 | 2015-07-03 | Intervet Int Bv | |
| CN102895660B (zh) * | 2012-10-25 | 2014-04-23 | 中国兽医药品监察所 | 一种鸭病毒性肝炎二价灭活疫苗 |
| US9950059B2 (en) | 2014-02-25 | 2018-04-24 | The United States Of America, As Represented By The Secretary Of Agriculture. | Immunogenic composition |
| CN110295149B (zh) * | 2019-06-24 | 2022-06-24 | 四川农业大学 | 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法 |
| US11299517B2 (en) * | 2020-04-15 | 2022-04-12 | The United States Of America, As Represented By The Secretary Of Agriculture | Recombinant vaccine against Marek's disease and Newcastle disease |
| CN116096410A (zh) * | 2020-04-20 | 2023-05-09 | 格雷菲克斯公司 | 工程化广泛反应性冠状病毒疫苗及相关设计和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3575A (en) * | 1844-05-06 | Improvement | ||
| US182241A (en) * | 1876-09-12 | Improvement in animal-traps | ||
| US4458630A (en) | 1982-06-22 | 1984-07-10 | The United States Of America As Represented By The Secretary Of Agriculture | Disease control in avian species by embryonal vaccination |
| WO1990002803A2 (en) * | 1988-09-13 | 1990-03-22 | Rhone-Merieux S.A. | Viral vaccines |
| AU6714290A (en) | 1989-10-02 | 1991-04-28 | Embrex Inc. | Method of treating infectious bursal disease virus |
| US5397568A (en) | 1989-10-02 | 1995-03-14 | Whitfill; Craig E. | Method of treating infectious bursal disease virus infections |
| US5056464A (en) | 1990-01-18 | 1991-10-15 | Embrex, Inc. | Automated injection system for avian embryos with advanced fluid delivery system |
| US5595912A (en) | 1990-05-04 | 1997-01-21 | University Of Maryland College Park | Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination |
| ZA924203B (en) | 1991-06-18 | 1993-03-31 | Akzo Nv | Coccidiosis poultry vaccine |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| JPH06141853A (ja) * | 1992-10-30 | 1994-05-24 | Chemo Sero Therapeut Res Inst | 組換え鶏伝染性喉頭気管炎ウイルス及びその製法 |
| EP0696204A4 (en) * | 1993-02-26 | 1999-03-31 | Syntro Corp | Recombined chickenpox virus and its use |
| EP0745127A4 (en) | 1994-01-11 | 1999-10-20 | Cornell Res Foundation Inc | CONTROLLING MARE'S DISEASE BY PREVENTING LATENCY AND DEVELOPING TUMOR CELLS |
| EP0772453A1 (en) | 1994-06-20 | 1997-05-14 | THE UNITED STATES OF AMERICA, reresented by THE SECRETARY, DEPARTMENT OF AGRICULTURE | In ovo immunization of avian embryos with oil-emulsion vaccines |
| US5817320A (en) | 1994-06-20 | 1998-10-06 | The United States Of America As Represented By The Secretary Of The Agriculture | In ovo immunization of avian embryos with oil-emulsion vaccines |
| JPH08116976A (ja) * | 1994-10-20 | 1996-05-14 | Chemo Sero Therapeut Res Inst | 免疫用核酸調製物およびこれを用いた免疫方法 |
| EP0837929A2 (en) | 1995-07-07 | 1998-04-29 | Nippon Zeon Co., Ltd. | Marek's disease virus genes and their use in vaccines for protection against marek's disease |
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| US5699751A (en) | 1996-10-02 | 1997-12-23 | Embrex, Inc. | Method and apparatus for in ovo injection |
| US6048535A (en) * | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
| JP4091152B2 (ja) * | 1997-09-19 | 2008-05-28 | 財団法人化学及血清療法研究所 | 金コロイドを含む核酸調製物 |
| US6286455B1 (en) | 1998-01-12 | 2001-09-11 | Embrex, Inc. | Automated in ovo injection apparatus |
| UY25347A1 (es) | 1998-01-12 | 1999-05-14 | Embrex Inc | Procedimiento de inyeccion multiple para el tratamiento de embriones aviarios in ovo, y aparato automatizado para la inyeccion in ovo. |
-
2003
- 2003-03-04 US US10/377,718 patent/US7029681B2/en not_active Expired - Lifetime
- 2003-03-06 AU AU2003216531A patent/AU2003216531B2/en not_active Ceased
- 2003-03-06 BR BRPI0308365A patent/BRPI0308365B1/pt not_active IP Right Cessation
- 2003-03-06 IL IL16385903A patent/IL163859A0/xx unknown
- 2003-03-06 CN CN200910212389A patent/CN101703770A/zh active Pending
- 2003-03-06 MX MXPA04008692A patent/MXPA04008692A/es active IP Right Grant
- 2003-03-06 CN CN038080001A patent/CN1646157B/zh not_active Expired - Fee Related
- 2003-03-06 EP EP03744203.5A patent/EP1490105B1/en not_active Expired - Lifetime
- 2003-03-06 WO PCT/US2003/006811 patent/WO2003075843A2/en not_active Ceased
- 2003-03-06 CA CA2478081A patent/CA2478081C/en not_active Expired - Fee Related
- 2003-03-06 JP JP2003574119A patent/JP4999258B2/ja not_active Expired - Fee Related
-
2004
- 2004-09-01 IL IL163859A patent/IL163859A/en not_active IP Right Cessation
-
2009
- 2009-06-17 JP JP2009144188A patent/JP2009203242A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111733143A (zh) * | 2012-03-30 | 2020-10-02 | 法国诗华动物保健公司 | 多价重组禽疱疹病毒和用于免疫禽类的疫苗 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1646157A (zh) | 2005-07-27 |
| WO2003075843A2 (en) | 2003-09-18 |
| CA2478081C (en) | 2011-04-19 |
| MXPA04008692A (es) | 2005-02-24 |
| JP2009203242A (ja) | 2009-09-10 |
| CA2478081A1 (en) | 2003-09-18 |
| WO2003075843A3 (en) | 2004-07-22 |
| IL163859A0 (en) | 2005-12-18 |
| EP1490105A2 (en) | 2004-12-29 |
| US20030175291A1 (en) | 2003-09-18 |
| AU2003216531B2 (en) | 2006-11-30 |
| CN1646157B (zh) | 2011-03-02 |
| JP4999258B2 (ja) | 2012-08-15 |
| EP1490105B1 (en) | 2013-10-02 |
| EP1490105A4 (en) | 2006-04-19 |
| JP2005519943A (ja) | 2005-07-07 |
| US7029681B2 (en) | 2006-04-18 |
| IL163859A (en) | 2010-05-17 |
| BR0308365A (pt) | 2005-09-06 |
| BRPI0308365B1 (pt) | 2016-12-27 |
| AU2003216531A1 (en) | 2003-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2658439C2 (ru) | Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц | |
| US6719979B2 (en) | Newcastle disease virus infectious clones, vaccines and diagnostic assays | |
| US6464984B2 (en) | Avian polynucleotide vaccine formula | |
| CA2166371A1 (en) | Avian herpesvirus-based live recombinant avian vaccine, in particular against gumboro disease | |
| CN113736800A (zh) | 一种鸽源新城疫病毒重组疫苗株及其构建方法和应用 | |
| JP2009203242A (ja) | インビボ（ｉｎｖｉｖｏ）マルチプルｄｎａワクチンと多価ｄｎａワクチン | |
| EP0520753B1 (en) | Recombinant fowlpox vaccine for protection against Marek's disease | |
| AU6274994A (en) | Recombinant fowlpox viruses and uses thereof | |
| WO1994019014A9 (en) | Recombinant fowlpox virus s-fpv-043 and uses thereof | |
| Ling et al. | Sequence and in vitro expression of the phosphoprotein gene of avian pneumovirus | |
| AU2004238246B2 (en) | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry | |
| AU6481996A (en) | Recombinant fowlpox viruses and uses thereof | |
| US7314715B2 (en) | Recombinant avian herpesvirus useful in vaccine production | |
| IL198505A (en) | Multivalent dna vaccine for in ovo injection | |
| Mosley et al. | Avian viral vector vaccines for infectious bursal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100512 |